Enzyme Replacement Therapy Market by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, and Others), Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), and Others), and End User (Hospitals and Infusion Centers & Home Healthcare Setting): Global Opportunity Analysis and Industry Forecast, 2021–2030
- ALL4676863
- 280 Pages
- September 2021
- Diagnostic and Biotech
Enzyme replacement therapy (ERT) is a medical treatment, which involves replacement or intravenously administration of artificial enzymes among patients who are suffering from chronic conditions resulting from enzyme deficiencies or malfunction. The therapy helps in replenishing the deficient enzymes in the patient’s body either through the intravenous (IV) or oral routes of administration. The IV route is widely accepted by people in which the replacement enzyme is administered directly into the bloodstream through a controlled drip of fluids. Replacement enzymes for ERT are derived from human, animal, and plant cells that are then genetically altered and processed before being given to the patient. By receiving these enzyme replacements, the body is able to successfully perform the functions inhibited by the deficiency. Enzyme replacement therapies are intended to increase the concentration of enzymes but not for modifying underline root cause of the disease.
The growth of the enzyme replacement therapy market is majorly driven by rise in prevalence of chronic and life-threatening lysosomal storage diseases such as Gaucher, Pompe, Fabry, and scid. Furthermore, initiatives taken by the government to increase awareness among people about the availability of ERT is expected to notably contribute toward the growth of the global market. However, high treatment cost and side effects associated with the therapy can significantly affect the growth of enzyme replacement therapy market.
New developments in therapies and increase in product pipeline analysis are expected to provide remunerative opportunities for the expansion of the enzyme replacement therapy market. In addition, the healthcare industry in emerging economies is developing at a significant rate, due to surge in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.
The global enzyme replacement therapy market is segmented into product, disease type, end user, and region. Depending on product, the market is segmented into agalsidase beta, imiglucerase, velaglucerase alfa, idursulfase, galsulfase, laronidase, and others. By disease type, it is categorized into Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis, exocrine pancreatic insufficiency (EPI), and others. On the basis of end user, it is fragmented into hospitals and infusion centers & home healthcare setting. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
This report provides comprehensive competitive analysis and profiles of prominent market players such as 3D Systems Corporation, Exone Company, Formlabs Inc., General Electric, Materialise NV, Oxferd Performance Materials, Inc., Organovo Holdings, Inc., Proto Labs, SLM Solutions Group AG, and Stratasys Ltd.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global enzyme replacement therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the products and end users of enzyme replacement therapy used across the globe.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product
• Agalsidase Beta
• Imiglucerase
• Velaglucerase Alfa
• Idursulfase
• Galsulfase
• Laronidase
• Others
By Disease
• Gaucher Disease
• Fabry Disease
• Pompe Disease
• Mucopolysaccharidosis
• Exocrine Pancreatic Insufficiency (EPI)
• Others
By End User
• Hospitals
• Infusion Centers & Home Healthcare Setting
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o Spain
o Italy
o UK
o Rest of Europe
• Asia-Pacific
o Australia
o Japan
o India
o China
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
• Abbvie Inc.
• Astrazeneca Plc.
• BioMarin Pharmaceutical Inc.
• Chiesi Farmaceutici S.P.A
• Digestive Care, Inc.
• Leadiant Biosciences, Inc.
• Nestle Health Science
• PFIZER, INC.
• SANOFI
• Takeda Pharmaceuticals
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in the prevalence of rare diseases
3.5.1.2.Availability of a wide range of enzyme replacement therapy
3.5.1.3.Increasing Government initiatives for rare diseases
3.5.2.Restraint
3.5.2.1.High cost of the treatment
3.5.3.Opportunity
3.5.3.1.New developments in therapies coupled with growing opportunities in emerging market
3.5.4.Impact analysis
3.6.COVID-19 impact analysis on the Enzyme replacement therapy market
CHAPTER 4:ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Agalsidase Beta
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.2.1.Agalsidase beta by end users
4.2.3.Market analysis, by country
4.3.Imiglucerase
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.2.1.Imiglucerase by end users
4.3.3.Market analysis, by country
4.4.Velaglucerase alfa
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.2.1.Velaglucerase alfa by end users
4.4.3.Market analysis, by country
4.5.Idursulfase
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.2.1.Idursulfase by end users
4.5.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
4.6.Galsulfase
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.2.1.Galsulfase by end users
4.6.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
4.7.Laronidase
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.2.1.Laronidase by end users
4.7.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
4.8.Others
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.2.1.Others by end users
4.8.3.Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
CHAPTER 5:ENZYME REPLACEMENT THERAPY, BY DISEASE TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Gaucher disease
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Fabry Disease
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Pompe Disease
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Mucopolysaccharidosis
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Exocrine pancreatic insufficiency EPI
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Others
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
CHAPTER 6:ENZYME REPLACEMENT THERAPY MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Infusion Centers & Home Healthcare Setting
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:ENZYME REPLACEMENT THERAPY MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America enzyme replacement therapy market, by product
7.2.3.North America infection surveillance services market, by disease type
7.2.4.North America infection surveillance services market, by end user
7.2.5.Market size and forecast, by country
7.2.5.1.U.S. Enzyme replacement therapy market, by product
7.2.5.2.U.S. Enzyme replacement therapy market, by disease
7.2.5.3.U.S. Enzyme replacement therapy market, by end user
7.2.5.4.Canada Enzyme replacement therapy market, by product type
7.2.5.5.Canada Enzyme replacement therapy market, by disease type
7.2.5.6.Canada Enzyme replacement therapy market, by end user
7.2.5.7.Mexico Enzyme replacement therapy market, by product
7.2.5.8.Mexico Enzyme replacement therapy market, by disease type
7.2.5.9.Mexico Enzyme replacement therapy market, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe infection surveillance services market, by product
7.3.3.Europe infection surveillance services market, by disease type
7.3.4.Europe infection surveillance services market, by end user
7.3.5.Market size and forecast, by country
7.3.5.1.Germany Enzyme replacement therapy market, by product
7.3.5.2.Germany Enzyme replacement therapy market, by disease type
7.3.5.3.Germany Enzyme replacement therapy market, by end user
7.3.5.4.France Enzyme replacement therapy market, by product
7.3.5.5.France Enzyme replacement therapy market, by disease type
7.3.5.6.France Enzyme replacement therapy market, by end user
7.3.5.7.UK Enzyme replacement therapy market, by product
7.3.5.8.UK Enzyme replacement therapy market, by disease type
7.3.5.9.UK Enzyme replacement therapy market, by end user
7.3.5.10.Italy Enzyme replacement therapy market, by product
7.3.5.11.Italy Enzyme replacement therapy market, by disease type
7.3.5.12.Italy Enzyme replacement therapy market, by end user
7.3.5.13.Spain Enzyme replacement therapy market, by product
7.3.5.14.Spain Enzyme replacement therapy market, by disease type
7.3.5.15.Spain Enzyme replacement therapy market, by end user
7.3.5.16.Rest of Europe Enzyme replacement therapy market, by product
7.3.5.17.Rest of Europe Enzyme replacement therapy market, by disease type
7.3.5.18.Rest of Europe Enzyme replacement therapy market, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific infection surveillance services market, by product
7.4.3.Asia-Pacific infection surveillance services market, by disease type
7.4.4.Asia-Pacific infection surveillance services market, by end user
7.4.5.Market size and forecast, by country
7.4.5.1.Japan Enzyme replacement therapy market, by product
7.4.5.2.Japan Enzyme replacement therapy market, by disease type
7.4.5.3.Japan Enzyme replacement therapy market, by end user
7.4.5.4.China Enzyme replacement therapy market, by product
7.4.5.5.China Enzyme replacement therapy market, by disease type
7.4.5.6.China Enzyme replacement therapy market, by end user
7.4.5.7.Australia Enzyme replacement therapy market, by product
7.4.5.8.Australia Enzyme replacement therapy market, by disease type
7.4.5.9.Australia Enzyme replacement therapy market, by end user
7.4.5.10.India Enzyme replacement therapy market, by product
7.4.5.11.India Enzyme replacement therapy market, by disease type
7.4.5.12.India Enzyme replacement therapy market, by end user
7.4.5.13.South Korea Enzyme replacement therapy market, by product
7.4.5.14.South Korea Enzyme replacement therapy market, by disease type
7.4.5.15.South Korea Enzyme replacement therapy market, by end user
7.4.5.16.Rest of Asia-Pacific Enzyme replacement therapy market, by product
7.4.5.17.Rest of Asia-Pacific Enzyme replacement therapy market, by disease type
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA infection surveillance services market, by product
7.5.3.LAMEA infection surveillance services market, by disease type
7.5.4.LAMEA infection surveillance services market, by end user
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil Enzyme replacement therapy market, by product
7.5.5.2.Brazil Enzyme replacement therapy market, by disease type
7.5.5.3.Brazil Enzyme replacement therapy market, by end user
7.5.5.4.Saudi Arabia Enzyme replacement therapy market, by product
7.5.5.5.Saudi Arabia Enzyme replacement therapy market, by disease type
7.5.5.6.Saudi Arabia Enzyme replacement therapy market, by end user
7.5.5.7.South Africa Enzyme replacement therapy market, by product
7.5.5.8.South Africa Enzyme replacement therapy market, by disease type
7.5.5.9.South Africa Enzyme replacement therapy market, by end user
7.5.5.10.Rest of LAMEA Enzyme replacement therapy market, by product
7.5.5.11.Rest of LAMEA Enzyme replacement therapy market, by disease type
7.5.5.12.Rest of LAMEA Enzyme replacement therapy market, by end user
CHAPTER 8:COMPANY PROFILES
8.1.ABBVIE INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.ASTRAZENECA PLC (ASTRAZENECA)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.3.BioMarin Pharmaceutical Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Chiesi Farmaceutici S.P.A
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Digestive Care, Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Product portfolio
8.6.Leadiant Biosciences, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Key strategic moves and developments
8.7.NESTLE S.A. (Nestlé Health Science S.A.)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.PFIZER, INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.SANOFI S.A.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Takeda Pharmaceutical Company Limited
8.10.1.Company overview
8.10.2.Operating business segments
8.10.3.Product portfolio
Takeda Pharmaceutical. offers the following enzyme replacement therapies:
8.10.4.Business performance
8.10.5.Key strategic moves and developments
TABLE 01.ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 02.AGALSIDASE BETA ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.ALGASIDAE BETA MARKET, BY END USER, 2020-2030($MILLION)
TABLE 04.IMIGLUCERASE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.IMIGLUCERASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 06.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07.VELAGLUCERASE ALFA MARKET, BY END USER, 2020-2030($MILLION)
TABLE 08.IDURSULFASE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09.IDURSULFASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 10.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GALSULFASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 12.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 13.LARONIDASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 14.ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15.OTHERS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 16.ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 17.GAUCHER DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.FABRY DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19.POMPE DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20.MUCOPOLYSACCHARIDOSIS ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 21.EXOCRINE PANCREATIC INSUFFICIENCY ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 22.OTHERS ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 23.ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24.ENZYME REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 25.INFUSION CENTERS & HOME HEALTHCARE SETTING ENZYME REPLACEMENT THERAPY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 26.ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 27.NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 28.NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 29.NORTH AMERICA INFECTION SURVEILLANCE SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30.NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 31.U.S. ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 32.U.S. ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE, 2020–2030
TABLE 33.U.S. ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 34.CANADA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 35.CANADA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 36.CANADA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 37.MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 38.MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 39.MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 40.EUROPE INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41.EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 42.EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43.EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 44.GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 45.GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 46.GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 47.FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 48.FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 49.FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 50.UK ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 51.UKENZYME REPLACEMENT THERAPY MARKET, BY INJURY TYPE, 2020–2030
TABLE 52.UK ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 53.ITALY ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 54.ITALY ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 55.ITALY ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 56.SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 57.SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 58.SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 59.REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 60.REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 61.REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 62.ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 63.ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 64.ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65.ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 66.JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 67.JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 68.JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 69.CHINA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 70.CHINA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 71.CHINA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 72.AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 73.AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 74.AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 75.INDIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 76.INDIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 77.INDIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 78.SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 79.SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 80.SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 81.REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 82.REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 83.REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 84.LAMEA INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 85.LAMEA INFECTION SURVEILLANCE SERVICES MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 86.LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 87.LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 88.BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 89.BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 90.BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 91.SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 92.SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 93.SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 94.SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 95.SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 96.SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 97.REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020–2030
TABLE 98.REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020–2030
TABLE 99.REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020–2030
TABLE 100.ABBVIE INC: COMPANY SNAPSHOT
TABLE 101.ABBVIE INC: OPERATING SEGMENTS
TABLE 102.ABBVIE INC: PRODUCT TYPE PORTFOLIO
TABLE 103.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 104.ASTRAZENECA: OPERATING SEGMENTS
TABLE 105.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 106.BIOMARIN: COMPANY SNAPSHOT
TABLE 107.BIOMARIN: OPERATING SEGMENTS
TABLE 108.BIOMARIN: PRODUCT PORTFOLIO
TABLE 109.CHIESI FARMACEUTICI.: COMPANY SNAPSHOT
TABLE 110.CHIESI FARMACEUTICI: OPERATING SEGMENTS
TABLE 111.MERCK: PRODUCT TYPE PORTFOLIO
TABLE 112.DIGESTIVE CARE: COMPANY SNAPSHOT
TABLE 113.SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 114.LEADIANT BIOSCIENCES: COMPANY SNAPSHOT
TABLE 115.LEADIANT BIOSCIENCES: PRODUCT TYPE PORTFOLIO
TABLE 116.NESTLE: COMPANY SNAPSHOT
TABLE 117.NESTLE: OPERATING SEGMENTS
TABLE 118.NESTLE: PRODUCT PORTFOLIO
TABLE 119.PFIZER INC: COMPANY SNAPSHOT
TABLE 120.PFIZER INC: PRODUCT TYPE PORTFOLIO
TABLE 121.SANOFI: COMPANY SNAPSHOT
TABLE 122.SANOFI: OPERATING SEGMENTS
TABLE 123.SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 124.TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 125.BIODIEM: OPERATING SEGMENTS
TABLE 126.TAKEDA PHARMACEUTICAL: PRODUCT PORTFOLIO
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
